Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 01, 2026
CME Group (CME) Drops -14.3% in 30 Days on Leadership Transition and Competitive Pressures

CME Group (CME) Drops -14.3% in 30 Days on Leadership Transition and Competitive Pressures

Key Takeaways

  • CME Group shares fell approximately 14.3% over the last 30 days, dropping from $257.76 on June 1, 2026, to $220.88 as of June 30, 2026.
  • The selloff was driven by a confluence of factors including the announced CEO succession plan, regulatory approval of competing perpetual futures products, and a new equity-index futures competitor entering the market.
  • Over the last quarter, the stock has declined roughly 33% from its March 2026 high of $329.16, reflecting sustained competitive and regulatory headwinds.
  • Despite the price decline, CME Group reported record Q1 2026 financial results with revenue of $1.9 billion and adjusted EPS of $3.36, both up significantly year-over-year.
  • Analyst sentiment remains mixed, with some firms downgrading price targets while others view the pullback as an attractive entry point given CME's dominant market position.

CME Group (CME) Company Overview and Market Position

CME Group is the world's leading derivatives marketplace, operating four major exchanges: the Chicago Mercantile Exchange (CME), Chicago Board of Trade (CBOT), New York Mercantile Exchange (NYMEX), and Commodity Exchange (COMEX). The company offers futures and options across all major asset classes including interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. CME also operates the BrokerTec fixed income platform and EBS foreign exchange platform, and provides central counterparty clearing through CME Clearing. With a market capitalization of approximately $80 billion, CME Group is a systemically important financial market utility that benefits from deep liquidity, network effects, and recurring revenue streams from transaction fees, clearing services, and market data.

CME Group (CME) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CME shares declined from $257.76 on June 1, 2026, to $220.88 as of June 30, 2026, representing a drop of approximately 14.3%. The stock experienced several sharp single-day declines during this period, including a 5.7% drop when a new equity-index futures competitor went live and a 3.4% decline tied to regulatory and competitive concerns. The quarterly performance has been even more pronounced, with CME falling roughly 33% from its March 2026 high of $329.16. The stock has breached multiple technical support levels, including its 50-day moving average, and has traded near or below its 52-week low of $244.56 reached in early June.

What Drove CME Stock Price in the Last 30 Days

Several major catalysts converged to pressure CME shares over the past month. The most significant was the June 17 announcement that longtime Chairman and CEO Terry Duffy will step down as Chief Executive Officer in March 2027, transitioning to Executive Chairman, with President and CFO Lynne Fitzpatrick succeeding him. While the succession is orderly and planned, the market reacted negatively to the uncertainty surrounding a leadership transition at a company so closely identified with Duffy's 25-year tenure, sending shares down approximately 4% on the news.

Compounding the leadership uncertainty, the CFTC's approval of perpetual futures contracts triggered a sector-wide selloff among exchange operators. Perpetual futures, or "perps," are crypto-native contracts that never expire and trade continuously, posing a potential competitive threat to CME's traditional expiry-based futures franchise. CME responded by suing the CFTC to block prediction-market platform Kalshi from offering perpetual futures, arguing such products threaten the integrity of regulated derivatives markets. Additionally, a rival exchange began trading Bloomberg-linked equity index futures, raising fears of market-share erosion in one of CME's core product areas. TD Cowen lowered its price target on CME from $332 to $273, citing concerns that perpetual futures could limit stock multiples across the exchange sector.

What Drove CME Stock Performance Over the Last Quarter

The broader quarterly decline reflects an accumulation of competitive and regulatory headwinds that have weighed on investor sentiment since late March. After reaching an all-time high of $329.16 in March 2026, CME shares began a steady descent as concerns mounted over the evolving competitive landscape. The CFTC's review of CME's proposal for 24/7 crude oil futures trading, combined with the emergence of new trading venues and products, created an overhang on the stock. The approval of perpetual futures in early June accelerated the selloff, as investors reassessed the long-term durability of CME's competitive moat. Despite reporting record Q1 2026 results in late April — including revenue of $1.9 billion, adjusted EPS of $3.36, and record average daily volume of 36.2 million contracts — the strong fundamentals were insufficient to offset the negative sentiment driven by structural concerns. Insider selling activity, including multiple sales by CEO Terry Duffy and other senior executives, added to the cautious tone.

Exploring AI Tools in Market Analysis

In volatile market environments like the one currently affecting CME Group, I often turn to data-driven tools to help identify opportunities and manage risk. As part of my routine research, I checked this setup using AI Trading Bots to see how automated strategies might align with the current technical picture. These tools scan patterns across thousands of tickers in real time, which can provide an additional quantitative layer when traditional analysis faces shifting competitive and regulatory variables.

CME Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several key factors will influence CME's stock trajectory. The outcome of CME's lawsuit against the CFTC regarding perpetual futures will be critical, as a favorable ruling could reinforce the company's regulatory moat while an adverse decision may accelerate competitive pressures. The upcoming Q2 2026 earnings report, expected around July 22, will provide updated visibility into trading volumes, revenue trends, and the contribution from new product initiatives including 24/7 cryptocurrency derivatives and prediction markets. Investors will also monitor the leadership transition timeline and any strategic signals from incoming CEO Lynne Fitzpatrick. Macroeconomic factors — including Federal Reserve policy decisions, geopolitical tensions in the Middle East affecting energy markets, and overall market volatility — will continue to drive trading activity across CME's asset classes. Analyst consensus price targets remain well above current levels, with a median target around $308, though sentiment will depend heavily on how competitive and regulatory dynamics evolve in the coming months.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CME

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CME in upward trend: 10-day moving average moved above 50-day moving average on July 30, 2026

The 10-day moving average for CME crossed bullishly above the 50-day moving average on July 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 14, 2026. You may want to consider a long position or call options on CME as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CME moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 267 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CME moved out of overbought territory on August 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CME broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.729) is normal, around the industry mean (5.815). P/E Ratio (23.323) is within average values for comparable stocks, (26.690). Projected Growth (PEG Ratio) (4.821) is also within normal values, averaging (3.218). CME has a moderately high Dividend Yield (0.041) as compared to the industry average of (0.020). CME's P/S Ratio (14.663) is slightly higher than the industry average of (8.451).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are CME Group (NASDAQ:CME).

Industry description

The financial publishing /services sector includes companies that provide informational products and services that are of value to investors, financial/analytics professionals and other interested readers. The products include real-time stock quotes, financial news and analyses. Think S&P Global, Inc., Moody`s Corporation, Thomson-Reuters Corp and IHS Markit Ltd. Information is critical in making financial or investment decisions, and what makes this industry’s output relevant at all times, across various economic conditions.

Market Cap

The average market capitalization across the Financial Publishing/Services Industry is 41.05B. The market cap for tickers in the group ranges from 3.1M to 127.14B. SPGI holds the highest valuation in this group at 127.14B. The lowest valued company is BTOG at 3.1M.

High and low price notable news

The average weekly price growth across all stocks in the Financial Publishing/Services Industry was 29%. For the same Industry, the average monthly price growth was 30%, and the average quarterly price growth was 19%. DTCX experienced the highest price growth at 35%, while BTOG experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Financial Publishing/Services Industry was 97%. For the same stocks of the Industry, the average monthly volume growth was 42% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 73
Price Growth Rating: 49
SMR Rating: 55
Profit Risk Rating: 79
Seasonality Score: -34 (-100 ... +100)
View a ticker or compare two or three
CME
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of securities and commodity exchanges

Industry FinancialPublishingServices

Profile
Details
Industry
Investment Banks Or Brokers
Address
20 South Wacker Drive
Phone
+1 312 930-1000
Employees
3875
Web
https://www.cmegroup.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
CME Group (CME) Drops -14.3% in 30 Days on Leadership Transition and Competitive Pressures